SCHEMBL5714359

SCHEMBL5714359

Cc1ccc(N2CCN(C(=O)Oc3ccc(CSc4ncc[nH]4)cc3)CC2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 3/20 0.44
HRH3 Q9Y5N1 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HPGD P15428 2/20 0.40
GPR119 Q8TDV5 1/20 0.40
ME2 P23368 3/20 0.39
ME1 P48163 3/20 0.39
ME3 Q16798 3/20 0.39
AOC3 Q16853 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
DRD5 P21918 1/20 0.37
DRD3 P35462 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714722 0.91 PANK3 (0.42) PANK3HRH3SMN1; SMN2KDM4EALDH1A1
SCHEMBL5714403 0.89 PANK3 (0.42) PANK3HRH3SMN1; SMN2ALDH1A1LMNA
SCHEMBL5715040 0.89 TRPA1 (0.44) PANK3SMN1; SMN2ALDH1A1MAPTMAPK1
SCHEMBL5715347 0.88 HRH3 (0.41) PANK3HRH3SMN1; SMN2KDM4EALDH1A1
SCHEMBL5715000 0.88 PANK3 (0.41) PANK3HRH3SMN1; SMN2KDM4EALDH1A1
SCHEMBL5714742 0.87 SMN1; SMN2 (0.53) HRH3SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5715306 0.86 HSD17B10 (0.51) SMN1; SMN2KDM4EALDH1A1LMNAMAPT
SCHEMBL5714025 0.85 SMN1; SMN2 (0.41) PANK3SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5714702 0.84 THRB (0.39) SMN1; SMN2KDM4EALDH1A1LMNAMAPT
SCHEMBL5715243 0.83 PANK3 (0.52) PANK3HRH3SMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885HRH3 1098/4885SMN1; SMN2 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.